^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Apoptosis inhibitor

    Related drugs:
    6d
    Chemical chaperone TUDCA rescues Insulin-mediated vascular relaxation via ER stress inhibition in diabetic rat model. (PubMed, Endocr Res)
    Insulin-mediated relaxation was impaired in diabetic rats (-56.7%) compared to controls (0%), accompanied by elevated ER stress markers and reduced eNOS, Akt, and IRS-1 expression. TUDCA treatment improved relaxation responses (-6.2%) significantly reduced ER stress markers and restored the expression of endothelial markers.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IRS1 (Insulin Receptor Substrate 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • NOS3 (Nitric oxide synthase 3) • PERK (Pancreatic EIF2-Alpha Kinase)
    7d
    GALPOL: Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    8d
    HELIOS: AMX0035 in Adult Patients With Wolfram Syndrome (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Amylyx Pharmaceuticals Inc. | Trial completion date: Dec 2026 --> May 2028
    Trial completion date
    9d
    AVH: Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis (clinicaltrials.gov)
    P=N/A, N=88, Not yet recruiting, Combined Military Hospital, Pakistan
    New trial
    13d
    Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine. (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    14d
    MILK-HI-TUDCA: TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Peking University First Hospital
    New P2 trial
    22d
    San-Huang-Chai-Zhu formula alleviates intrahepatic cholestasis through PPARα-mediated bile acid homeostasis and MKK4/JNK pathway. (PubMed, Cytotechnology)
    The therapeutic potential of SHCZF was evaluated in alpha-naphthylisothiocyanate (ANIT)-induced IC rat model, with ursodeoxycholic acid (UDCA) used as positive control...Importantly, GW6471 altered the regulatory effects of SHCZF on MKK4/JNK pathway and bile acid homeostasis. SHCZF improves IC by regulating PPARα-mediated bile acid homeostasis and MKK4/JNK pathway.
    Journal
    |
    MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    25d
    Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase inhibitor resistance in hepatocellular carcinoma. (PubMed, Cancer Lett)
    Mechanistic assays revealed that ursodeoxycholic acid (UDCA) upregulated BSEP and reversed resistance via an FXR-independent mechanism: UDCA directly binds cortactin (CTTN), reduces its PRMT1-dependent mono-methylation, and promotes CTTN degradation via chaperone-mediated autophagy, thereby enabling YY1 nuclear translocation and transcriptional activation of BSEP. Clinical specimen analyses corroborated an inverse BSEP-CTTN relationship and UDCA modulation. These findings identify impaired BSEP-mediated BA efflux and GCA accumulation as metabolic features of TKI resistance and support targeting the CTTN/YY1/BSEP axis, including UDCA, to overcome resistance.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • PRMT1 (Protein Arginine Methyltransferase 1) • CTTN (Cortactin) • YY1 (YY1 Transcription Factor)
    29d
    Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway. (PubMed, Drug Des Devel Ther)
    These findings suggest that UDCA exerts its anti-tumor effects primarily through direct inhibition of the EGFR-mediated PI3K/Akt/mTOR pathway, accompanied by partial restoration of the intestinal immune-metabolic microenvironment. This study provides new mechanistic insights supporting the therapeutic application of UDCA in CRC.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    1m
    Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia (clinicaltrials.gov)
    P4, N=80, Recruiting, Amira Adel Fouly | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Oct 2024 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    1m
    TUDCA as a Therapy for Ulcerative Colitis (UC) (clinicaltrials.gov)
    P1, N=14, Completed, Washington University School of Medicine | Recruiting --> Completed
    Trial completion
    1m
    Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. (PubMed, J Immunother Cancer)
    Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis.
    Journal • Checkpoint inhibition
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)